Skinflammation and drug toxicity-A delicate balance

Science Translational Medicine

Volumn 5, Issue 199, 2013, Pages

  Lacouture, Mario E ^a   Rodeck, Ulrich ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Thomas Jeferson University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CETUXIMAB; CLAUDIN 1; CLAUDIN 2; CORTICOSTEROID; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB;

ACNE; ADAPTIVE IMMUNITY; ALOPECIA; CLAUDIN 1 GENE; CLAUDIN 2 GENE; DERMATITIS; DRUG ERUPTION; EPIDERMIS; FACIAL HYPERTRICHOSIS; HAIR DISEASE; HUMAN; HYPERTRICHOSIS; INNATE IMMUNITY; KERATINOCYTE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARONYCHIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; REVIEW; SKIN TOXICITY; XEROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; EXANTHEMA; FEMALE; HUMANS; MALE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN;

EID: 84883856329     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006993     Document Type: Review

References (10)

1. M. E. Lacouture, Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6, 803-812 (2006).
2. F. Mascia, G. Lam, C. Keith, C. Garber, S. M. Steinberg, E. Kohn, S. H. Yuspa, Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci. Transl. Med. 5, 199ra110 (2013).
3. B. M. Lichtenberger, P. A. Gerber, M. Holcmann, B. A. Buhren, N. Amberg, V. Smolle, H. Schrumpf, E. Boelke, P. Ansari, C. Mackenzie, A. Wollenberg, A. Kislat, J. W. Fischer, K. Röck, J. Harder, J. M. Schröder, B. Homey, M. Sibilia, Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci. Transl. Med. 5, 199ra111 (2013).
4. F. Mascia, V. Mariani, G. Girolomoni, S. Pastore, Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163, 303-312 (2003).
5. F. Mascia, C. Cataisson, T. C. Lee, D. Threadgill, V. Mariani, P. Amerio, C. Chandrasekhara, G. Souto Adeva, G. Girolomoni, S. H. Yuspa, S. Pastore, EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J. Invest. Dermatol. 130, 682-693 (2010).
6. M. Sibilia, E. F. Wagner, Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269, 234-238 (1995).
7. D. Surguladze, D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, Y. Wu, J. Doody, D. J. Mauro, L. Witte, K. J. Busam, B. Pytowski, U. Rodeck, J. R. Tonra, Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res. 69, 5643-5647 (2009).
8. R. E. Eilers Jr., M. Gandhi, J. D. Patel, M. F. Mulcahy, M. Agulnik, T. Hensing, M. E. Lacouture, Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J. Natl. Cancer Inst. 102, 47-53 (2010).
9. M. E. Lacouture, E. P. Mitchell, B. Piperdi, M. V. Pillai, H. Shearer, N. Iannotti, F. Xu, M. Yassine, Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 1351-1357 (2010).
10. M. E. Lacouture, U. Rodeck, Skinflammation and drug toxicity-A delicate balance. Sci. Transl. Med. 5, 199fs33 (2013).